Adjuvant chemoimmunotherapy with LMF + BCG in node-negative and node-positive breast cancer patients. Intermediate report of a randomized trial in 242 patients. 1978

H J Senn, and W F Jungi, and R Amgwerd, and F Sprenger, and R Hochueli, and G Engelhart, and C Heinz, and A Wick, and F Enderlin, and G Creux, and B Simeon, and R Lanz, and R Bigler

UI MeSH Term Description Entries
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008408 Mastectomy Surgical procedure to remove one or both breasts. Mammectomy,Mammectomies,Mastectomies
D008593 Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age. Change of Life, Female
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002699 Chlorambucil A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed) 4-(Bis(2-chloroethyl)amino)benzenebutanoic Acid,Amboclorin,CB-1348,Chloraminophene,Chlorbutin,Leukeran,Lympholysin,N,N-Di-(2-chloroethyl)-p-aminophenylbutyric Acid,NSC-3088,CB 1348,CB1348,NSC 3088,NSC3088
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU

Related Publications

H J Senn, and W F Jungi, and R Amgwerd, and F Sprenger, and R Hochueli, and G Engelhart, and C Heinz, and A Wick, and F Enderlin, and G Creux, and B Simeon, and R Lanz, and R Bigler
February 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
H J Senn, and W F Jungi, and R Amgwerd, and F Sprenger, and R Hochueli, and G Engelhart, and C Heinz, and A Wick, and F Enderlin, and G Creux, and B Simeon, and R Lanz, and R Bigler
November 2023, European journal of cancer (Oxford, England : 1990),
H J Senn, and W F Jungi, and R Amgwerd, and F Sprenger, and R Hochueli, and G Engelhart, and C Heinz, and A Wick, and F Enderlin, and G Creux, and B Simeon, and R Lanz, and R Bigler
January 1992, Acta oncologica (Stockholm, Sweden),
H J Senn, and W F Jungi, and R Amgwerd, and F Sprenger, and R Hochueli, and G Engelhart, and C Heinz, and A Wick, and F Enderlin, and G Creux, and B Simeon, and R Lanz, and R Bigler
January 2000, Tumori,
H J Senn, and W F Jungi, and R Amgwerd, and F Sprenger, and R Hochueli, and G Engelhart, and C Heinz, and A Wick, and F Enderlin, and G Creux, and B Simeon, and R Lanz, and R Bigler
October 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
H J Senn, and W F Jungi, and R Amgwerd, and F Sprenger, and R Hochueli, and G Engelhart, and C Heinz, and A Wick, and F Enderlin, and G Creux, and B Simeon, and R Lanz, and R Bigler
October 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
H J Senn, and W F Jungi, and R Amgwerd, and F Sprenger, and R Hochueli, and G Engelhart, and C Heinz, and A Wick, and F Enderlin, and G Creux, and B Simeon, and R Lanz, and R Bigler
November 2015, The New England journal of medicine,
H J Senn, and W F Jungi, and R Amgwerd, and F Sprenger, and R Hochueli, and G Engelhart, and C Heinz, and A Wick, and F Enderlin, and G Creux, and B Simeon, and R Lanz, and R Bigler
January 2015, The New England journal of medicine,
H J Senn, and W F Jungi, and R Amgwerd, and F Sprenger, and R Hochueli, and G Engelhart, and C Heinz, and A Wick, and F Enderlin, and G Creux, and B Simeon, and R Lanz, and R Bigler
July 2002, Journal of the National Cancer Institute,
H J Senn, and W F Jungi, and R Amgwerd, and F Sprenger, and R Hochueli, and G Engelhart, and C Heinz, and A Wick, and F Enderlin, and G Creux, and B Simeon, and R Lanz, and R Bigler
January 2004, Acta oncologica (Stockholm, Sweden),
Copied contents to your clipboard!